BLCO logo

BAUSCH + LOMB CORP

BLCONYSE
πŸ† #1005 by market capEarnings Nov 4US Equity
$472.08β–Ό $16.95 (βˆ’3.59%)
Simulated price
1hβ€”
24hβ–Ό 3.6%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$6.03B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+6.5%
Slowing
πŸ“ŠGross Margin
57.2%
Healthy
πŸ’΅FCF Margin
2.6%
Thin
βš–οΈP/S Ratio
1.1x
Cheap
Otter Score
48
Weak
No chart data available for BLCO.

Trading Snapshot

Day Range
$465.22 – $474.13
52-Week Range
$13.77 – $18.92
Volume
$2.61B
Avg Volume
$3.07B
Shares Outstanding
357.2M
Next Earnings
Oct 20, 2026

Fundamentals Snapshot

Annual Revenue
$5.10B
Last Q Revenue
$1.39B
P/E Ratio
-35.3
P/S Ratio
1.1x
EPS (TTM)
$-0.48
Dividend Yield
0.00%

Why Investors Own BLCO

  • βœ“High-growth profile β€” revenue up +40.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 48% gross margin and 29% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$5.10Bβ–² +39.8% YoY
Gross Margin (TTM)
47.8%β–² +3.9% YoY
Operating Income (TTM)
$1.85Bβ–² +39.8% YoY
Free Cash Flow (TTM)
$1.49Bβ–² +39.8% YoY

About BAUSCH + LOMB CORP

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100

Analyst Price Target

β“˜
Average Target
$604.60
β–² +28.1% Upside
High Target$691.71
Low Target$558.20
Based on 29 analysts

Latest News & Updates